Proven Weight Loss With Lasting Impact
Patients treated with BELVIQ® were 3 to 4 times more likely to achieve ≥10% weight loss vs. placebo in studies of more than 6600 patients1.
CI=confidence interval; OR=odds ratio
Two-thirds of patients who continued taking BELVIQ® beyond Year 1 maintained clinically meaningful weight loss through Year 2BLOOM 2-Year Data >
*The effect of BELVIQ® on cardiovascular morbidity and mortality has not been established.Impact on BP, HR, and Other Cardiometabolic Parameters >
BELVIQ is also available as a simple, once-daily formulation proven to be slowly absorbed in the body and last throughout the day. Bioequivalence was demonstrated between 20 mg, once-daily XR formulation and 10 mg, twice-daily dosing for BELVIQ.Dosing & Administration >
In 2016, the U.S. Food and Drug Administration (FDA) approved BELVIQ XR, an extended-release formulation of lorcaserin. BELVIQ XR offers simple, once-daily dosing for your patients, and can be taken with or without food.
In a phase 1 clinical trial,* BELVIQ XR extended-release, 20 mg tablets administered once daily were compared with the immediate-release formulation of BELVIQ 10 mg tablets administered twice daily and were found to be bioequivalent.3
Effect of food: There was no significant food effect on the rate or extent of absorption of BELVIQ XR.
*in 34 healthy patients
BELVIQ/BELVIQ XR is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidemia, type 2 diabetes).
Limitations of Use:
BELVIQ®/BELVIQ XR® is a federally controlled substance (CIV) because it may be abused or lead to dependence.
For more information about BELVIQ®/BELVIQ XR®, see full Prescribing Information.